The life-extending drug is allowed in Scotland and not England
Scotland is also the only place in the UK where patients can get a pill that cuts the risk of HIV infection by 90 per cent.
Scottish public spending is £10,500 for each person compared to £8,800 in England.
The drug will be removed from the NHS in England in June, which has sparked a backlash from breast cancer patients and campaign groups.
The cancer treatment will be available in Scotland but not England
Signs and symptoms of Breast cancer
Thu, October 6, 2016
Breast cancer is the most common cancer in women; and one in eight women in the UK will develop the disease during their lifetime. These are the symptoms to check for.
1 of 8
Discharge, rash or dimpling? These are the symptoms to check for
t is imperative that we avoid a completely unacceptable situation where, in future, people with incurable breast cancer in Scotland can access this life-extending drug but those in England cannot
Danni Manzi of Breast Cancer Care
Get Quotes on Home Insurance
Patients in England can get the treatment through the Cancer Drugs Fund but it has not been made available by the National Institute for Heath and Care Excellence.
The Barnett formula means that English and Welsh taxpayers contribute more to Scottish health spending.
The drug Kadcyla can prolong a breast cancer sufferer’s life by up to nine months.
The drug could extend a cancer-sufferers life by nine months
One hundred patients a year in Scotland will benefit from the drug following its approval by the Scottish Medicines Consortium (SMC).
The SMC has said the drug would enable patients to spend "more time with their families and in some cases return to work".
Danni Manzi, of Breast Cancer Care, said: “It is imperative that we avoid a completely unacceptable situation where, in future, people with incurable breast cancer in Scotland can access this life-extending drug but those in England cannot.”
Baroness Morgan of Drefelin, Breast Cancer Care’s chief executive, said: “Thousands of patients in England, Wales and Northern Ireland are still living in desperate hope that Kadcyla will also be made available to them on the NHS.
“We very much hope that this crucial life-extending drug will not be denied to women that need it.”
Kadcyla combines Herceptin with a chemotherapy, which allows a stronger dose with fewer side-effects.